$HSIC

Henry Schein (HSIC) announced a U.S. distribution deal with Applied BioCode for its BioCode MDx-3000 platform. The company faces recalls of dental products due to packaging issues. Analysts project $15.4B revenue and $661.2M earnings by 2029, with a 12% potential upside. Recent recalls add operational scrutiny but are not expected to significantly impact the company's growth narrative.

Henry Schein, Inc. [HSIC] outlined plans to accelerate growth, simplify operations, and improve operating income by $200 million, targeting double-digit EPS growth. The company highlighted strong performance in dental and medical segments, focusing on consumables, private label, and technology. Leadership emphasized disciplined M&A and share buybacks for capital allocation.

Albertini Andrea (CEO, Global Dist. & Tech.) sold (to issuer) 3,984 shares of HENRY SCHEIN INC (HSIC) on 2026-09-08.

Henry Schein (HSIC) became an approved supplier for DermaSensor's FDA-cleared skin cancer detection device, expanding its distribution. Analysts project HSIC's revenue at $15.4B and earnings at $661.2M by 2029, a 9% upside. The partnership supports HSIC's shift toward higher-margin technology offerings, but investors should consider pricing pressures and customer bargaining power.

Henry Schein (HSIC) is identified as a potential value stock with a Zacks Rank #2 (Buy) and a Value grade of A. Its P/E ratio of 13.27 is below its industry average of 17.58, and it shows attractive PEG, P/B, P/S, and P/CF ratios compared to industry averages. The analysis suggests HSIC may be undervalued.

Henry Schein, Inc. (HSIC) reported broad-based growth in Q2, with sales increases across distribution, specialty products, and technology. Management raised its 2026 sales and earnings guidance. HSIC trades at a discount to market benchmarks but faces risks from leverage and execution challenges. The company aims for $200M in operating income improvement by 2026, with savings initiatives underway.

BTIG raised its price target on Henry Schein to $110 from $100 while maintaining a Buy rating. The stock is currently trading at $89.57, up 0.38% on the day but down 1.28% over the past year. Barclays also recently adjusted its target to $100 from $86.

Henry Schein (HSIC) reported Q2 2026 sales of $3,458 million and net income of $94 million, both up year over year, with higher EPS from continuing operations. On Aug. 4, 2026, management raised full-year 2026 total sales growth guidance to 4.5% to 5.5% from 3% to 5%, citing stronger momentum.

Henry Schein (HSIC) reported Q2 2026 net sales of $3.5 billion, up 6.7%, and non-GAAP diluted EPS of $1.27. GAAP diluted EPS was $0.82. The company raised 2026 guidance, including non-GAAP EPS to $5.29 to $5.39 and sales growth to 4.5% to 5.5%, and approved $200 million in share repurchases.

Henry Schein Inc. outlined a transformation focused on AI, simpler leadership, and faster execution in its first earnings report under CEO Fred Lowery. The company reported Q2 net sales of $3.46B (+6.7%) and net income of $94M (+9.3%), raised its 2026 sales outlook to 4.5% to 5.5%, and announced a leadership reorganization integrating supply chain and distribution. It targets $200M+ operating improvements.